Lupus & antiphospholipid syndrome
Prevalence and outcomes of a pilot definition of severe refractory systemic lupus erythematosus: observations from a multinational Asia-Pacific cohort
Authors' conclusion
A draft definition of srSLE was clearly associated with poor outcomes.
Study context
- Population
- Patients with SLE in a 13-country Asia-Pacific longitudinal cohort, data collected prospectively 2013–2020
- Participants
- 3,744 patients1,810 severe refractory systemic lupus erythematosus (srSLE) visits
- Outcome
- Prevalence of srSLE (pilot definition) and outcomes: disease activity, medication use and T2T endpoint attainment
- Follow-up
- 12 months
Methodological detailsmultinational, longitudinal, 13-country
- Multinational
- Longitudinal
- 13-country
Main finding
As reported in the abstract
srSLE prevalence
srSLE
14%
578
Observational data: associations, not effects.
Further findings
SLEDAI-2K after the srSLE index visit · 6m and 12m
- Median [IQR] SLEDAI-2K at 6m and 12m (12 [10, 14] at the index visit)
- 6 [4, 10]
Medication use during follow-up · all follow-up time points
- Most patients remained on combination anti-malarial, glucocorticoids (GC) and immunosuppressants (IS)
GC dose at the index visit
- Median [IQR] GC dose
- 10 [5, 20] mg/day
GC dose · 6m
- Median [IQR] GC dose
- 8 mg [5.0, 12.9]
GC dose · 12m
- Median [IQR] GC dose
- 5 mg [5.0, 10.0]
Treat-to-target (T2T) endpoint attainment · over 12 months
- GC-free remission
- 1%
- Less than a quarter of patients attained LLDAS
Original publication
Prevalence and outcomes of a pilot definition of severe refractory systemic lupus erythematosus: observations from a multinational Asia-Pacific cohort. Arthritis Res Ther. Published 23 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →